Cancer Invest. 1990;8(3-4):327-34.

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.

Cocconi G, Lottici R, Bisagni G, Bacchi M, Tonato M, Passalacqua R, Boni C, Belsanti V, Bassi P.

Source

Medical Oncology Department, University Hospital, Parma.

Abstract

Twenty-two consecutive patients with brain metastases from breast carcinoma were treated with a combination of platinum (100 mg/m2 day 1) and etoposide (100 mg/m2 days 4, 6, 8) every three weeks. Five (23%) achieved a complete response (CR) while 7 (32%) obtained a partial response (PR) for an overall response rate of 55%. The 95% confidence interval for combined CR and PR was 34-76%. Five patients received brain irradiation after reaching the maximum degree of objective remission by chemotherapy. Median duration of combined CR plus PR was 40 weeks (12+; 152). Median duration of survival was 58 weeks (2; 208+). Fifty-five percent of the patients were alive at one year. Our study demonstrates that this combination treatment is highly effective in the management of brain metastases from breast carcinoma.

PMID:: 2207757; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Brain Cancer - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. [Cancer. 1999]
Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
Franciosi V, Cocconi G, Michiara M, Di Costanzo F, Fosser V, Tonato M, Carlini P, Boni C, Di Sarra S. Cancer. 1999 Apr 1; 85(7):1599-605.
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer. [BMC Cancer. 2006]
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
Orlando L, Cardillo A, Ghisini R, Rocca A, Balduzzi A, Torrisi R, Peruzzotti G, Goldhirsch A, Pietri E, Colleoni M. BMC Cancer. 2006 Sep 15; 6:225. Epub 2006 Sep 15.
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer. [J Chemother. 2007]
Mitoxantrone plus vinorelbine in pretreated patients with metastatic breast cancer.
Onyenadum A, Gogas H, Markopoulos C, Bafaloukos D, Aravantinos G, Mantzourani M, Koutras A, Tzorakoelefterakis E, Xiros N, Makatsoris T, et al. J Chemother. 2007 Oct; 19(5):582-9.
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer. [Ann Oncol. 1997]
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer.
Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R. Ann Oncol. 1997 Jan; 8(1):57-64.
Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group. [Jpn J Clin Oncol. 1994]
Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K. Jpn J Clin Oncol. 1994 Oct; 24(5):275-81.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

Combination therapy with platinum and etoposide of brain metastases from breast ...
Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.
Cancer Invest. 1990 ;8(3-4):327-34.

PubMed
Actinic granuloma occurring in an unusual association with cutaneous B-cell chro...
Actinic granuloma occurring in an unusual association with cutaneous B-cell chronic lymphocytic leukemia.
J Cutan Pathol. 2012 Feb ;39(2):294-7. doi: 10.1111/j.1600-0560.2011.01811.x. Epub 2011 Nov 12 .

PubMed
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
N Engl J Med. 2011 Dec 22 ;365(25):2366-76. Epub 2011 Nov 12 .

PubMed
Institutional research misconduct.
Institutional research misconduct.
BMJ. 2011 Nov 9 ;343:d7284. doi: 10.1136/bmj.d7284.

PubMed
Commentary: I see no convincing evidence of "enterocolitis," "colitis," or a "un...
Commentary: I see no convincing evidence of "enterocolitis," "colitis," or a "unique disease process".
BMJ. 2011 Nov 9 ;343:d6985. doi: 10.1136/bmj.d6985.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information